Laviana Pharma on the "TOP 10 Most Growing CXO Companies" List

The 6th China Bio-Pharm Partnering Forum was held in Suzhou from 4th - 5th August 2022. With its outstanding performance in multiple fields, such as innovative R&D, commercialization, and corporate growth, Laviana Pharma was selected as one of the “China Bio-Pharm Industry Value List 2022 - Top 10 Most Growing CXO Companies”.

 The forum focused on the leading-edge technical information and the interpretation of the latest industrial policies. More than 200 authoritative leaders and 1,500 industry experts participated in more than 10 seminars. The forum comprehensively linked multiple platforms of industry, university, research, and capital through the keynote speeches, round-table discussions, business negotiation, award ceremony, and other activities to build a Bio-Pharm industry innovation cluster with international competitiveness and global influence. Through innovative technology empowerment and key location layout, Laviana Pharma will constantly have further investment in R&D and production. Now, Laviana Pharma is home to more than 480 employees, growing by nearly 60% compared with 2020. The number of R&D staff has increased to more than 200, with 30% of professional staff with master’s degrees or above. In addition, Laviana Pharma continues to invest in the enhancement of R&D and production capacity, accelerating the construction of the GMP production base in Cangzhou and launching the production base project in Anhui to further improve the comprehensive service capacity. Due to its investment in R&D and production, Laviana Pharma maintains its growth and vitality in the competitive environment, and has developed into a player widely known and praised by industry insiders.